Skip to main content

Table 3 Demographic and anthropometric data, body composition, laboratorial findings, juvenile dermatomyositis (JDM) scores and treatment in JDM patients with and without gingivitis

From: Juvenile dermatomyositis: is periodontal disease associated with dyslipidemia?

Variables JDM with gingivitis (GBI > 25%, n = 12) JDM without gingivitis (GBI ≤ 25%, n = 12) p
Demographic data
 Current age, years 12.4 (8.3–18.4) 9.2 (5.5–17.5) 0.034
 Age at disease presentation, years 4.8 (3.7–7.4) 5.2 (4.1–9.5) 0.580
 Disease duration, years 7.09 ± 3.07 3.95 ± 2.1 0.008
 Female gender 9 (75) 5 (41) 0.182
Anthropometric data
 BMI, kg/m2 19.6 (14.5–30) 19.2 (15.3–25) 0.954
Body composition
 Fat percentual 28.2 (11.1–45.4) 26 (10.9–42) 0.789
 Fat mass, kg 10.8 (5.0–27.1) 8.2 (2.9–20.2) 1.000
 Lean mass, kg 26.4 (15.4–43.8) 27.2 (20–44.5) 0.423
Lipid profile
 Total cholesterol 151 (115–206) 151 (102–227) 0.913
  ≥ 170 mg/dL 5 (41) 3 (25) 0.666
 HDL, mg/dL 43 (0–65) 49 (17–72) 0.328
  ≤ 45 mg/dL 9 (75) 4 (33) 0.099
 LDL, mg/dL 92 (76–148) 77.5 (56–129) 0.265
  ≥ 130 mg/dL 1 (9) 0 1.000
 VLDL, mg/dL 16 (9–42) 14.5 (9–68) 0.957
 Triglycerides, mg/dL 82 (31–168) 72.5 (46–340) 0.935
  ≥130 mg/dL 1 (8) 3 (33) 0.316
Anti-LPL antibody 0 1 (8) 1.000
Muscle enzymes
 AST, U/L 28 (13–122) 29.5 (15–82) 0.703
 ALT, U/L 36 (22–123) 34 (29–79) 0.744
 CK, U/L 84 (33–478) 125 (62–179) 0.399
 LDH, U/L 184 (107–1234) 216.5 (153–562) 0.355
 Aldolase, U/L 5.7 (3.4–10.8) 6.35 (4.6–14.6) 0.231
Inflammatory profile
 ESR, mm/1SThour 20 (2–40) 19 (7–54) 0.624
 CRP, mg/dL 0.59 (0.16–5.5) 1.61 (0.15–26) 0.242
JDM scores
 CMAS, 0–52 52 (10–52) 52 (17–52) 0.848
 MMT, 0–80 80 (42–80) 80 (38–80) 0.742
 DAS, 0–18 4 (0–12) 3 (0–18) 0.807
 Cutaneous DAS, 0–9 1 (0–8) 1 (0–9) 0.663
 Muscle DAS 2 (0–9) 2 (0–9) 0.853
 MYOACT, 0–1 0.05 (0–0.16) 0.02 (0–0.3) 0.724
 MITAX, 0–1 0.01 (0–0.23) 0 (0–0.28) 0.462
 CHAQ 0 (0–1.75) 0.625 (0–2.5) 0.164
Treatment
 Prednisone    
  Current use 1 (8) 8 (66) 0.303
  Cumulative dose, g 13.6 (4.9–51.5) 15.1 (3.9–31.2) 0.531
 Methotrexate    
  Current use 3 (25) 8 (66) 0.277
  Cumulative dose, g 2.2 (0.3–16.9) 1.9 (0.37–4.98) 0.79
 Cyclosporine    
  Current use 0 3 (25) 0.230
  Cumulative dose, g 0 (0–3.6) 0 0.805
  1. Values expressed in mean ± SD, median (range) and n (%), GBI (gingival bleeding index), BMI (body mass index), HDL (high density lipoprotein), LDL (low density lipoprotein), VLDL (very low density), anti-LPL (anti-lipoprotein lipase antibody), AST (aspartate aminotransferase), ALT (alanine aminotransferase), CK (creatine kinase), LDH (lactate dehydrogenase), ESR (erythrocyte sedimentation rate), CRP (C-reactive protein), CMAS (Childhood Myositis Assessment Scale), MMT (Manual Muscle Testing), DAS (Disease Activity Score), MYOACT (Myositis Disease Activity Assessment Analogue Scale), MYTAX (Myositis Intention To Treat Activity Index), CHAQ (childhood assessment questionnaire)